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ABSTRACT
Familial hypercholesterolaemia (FH) is a common
autosomal-dominant disorder in most European
countries. Patients with FH are characterised by a raised
level of low-density lipoprotein cholesterol and a high
risk of premature coronary heart disease (CHD). Currently
there is no consensus regarding the clinical utility to
predict future coronary events or testing for the presence
of subclinical atherosclerotic disease in asymptomatic
patients with FH. Family screening of patients with FH as
recommended by the UK National Institute of Health and
Care Excellence guideline would result in ﬁnding many
young individuals with a diagnosis of FH who are
clinically asymptomatic. The traditional CHD risk scores,
that is, the Framingham score, are insufﬁcient in risk
prediction in this group of young individuals. In addition,
a better understanding of the genetic aetiology of the
FH phenotype and CHD risk in monogenic FH and
polygenic hypercholesterolaemia is needed. Non-invasive
imaging methods such as carotid intima-media thickness
measurement might produce more reliable information in
ﬁnding high-risk patients with FH. The potential market
authorisation of novel therapeutic agents such as PCSK9
monoclonal inhibitors makes it essential to have a better
screening programme to prioritise the candidates for
treatment with the most severe form of FH and at higher
risk of coronary events. The utility of new imaging
techniques and new cardiovascular biomarkers remains
to be determined in prospective trials.
INTRODUCTION
Familial hypercholesterolaemia (FH) is a common
autosomal-dominant disorder with the frequency
of heterozygous FH estimated at 1 in 200–500 in
most European populations.1 The clinical diagnosis
of FH is based on a raised low-density lipoprotein
cholesterol (LDL-C) level of >4.9 mmol/L, physical
stigmata, for example, tendon xanthomata or evi-
dence of these signs in ﬁrst-degree or second-
degree relatives and having a personal or family
history of premature coronary heart disease
(CHD).2 Mutations in three genes, the
LDL-receptor gene (LDLR), the gene coding for
apolipoprotein B (APOB) and the gene encoding
the proprotein convertase subtilisin/kexin type 9,
are responsible for causing FH. In practice, around
60% of the patients with a clinical diagnosis of FH
do not have a detectable mutation in any of these
three common genes3 and in such patients it has
been suggested that there is most likely to be a
polygenic cause for their raised LDL-C level.4
CHD is the biggest cause of mortality and mor-
bidity in individuals diagnosed with FH. Data from
the Simon Broome Registry showed that the cumu-
lative risk of a fatal or non-fatal coronary event in
the patients with FH by the age of 60 years
without effective treatment is at least 50% in men
and 30% in women with a marked increase in post-
menopausal women.5 The coronary mortality was
reported to be fourfold higher in people with a
clinical diagnosis of deﬁnite FH compared with the
general population.6
The 2008 National Institute of Health and Care
Excellence (NICE) guideline on FH recommends
cascade screening for ﬁrst-degree relatives of all
patients with a clinical diagnosis of FH.2 This
would result in ﬁnding many individuals with a
diagnosis of FH who are clinically asymptomatic.
Risk stratiﬁcation of subclinical coronary athero-
sclerosis in asymptomatic patients with FH who are
at higher risk of advanced CHD is important, as
these people might be eligible for intensive treat-
ment at a younger age. There is currently no reli-
able screening test available to predict prevalence
and progression of atherosclerosis and major
adverse cardiovascular events in asymptomatic indi-
viduals with FH. The purpose of this paper is to
review the current evidence on cardiovascular risk
stratiﬁcation in this group.
CHD RISK IN HETEROZYGOUS FH
Premature CHD is an established phenomenon of
FH, with the average mean age of onset of coron-
ary symptoms shown to be 45 years in men and
55 years in women.5 Because the physical stigmata
of FH develop later in life, establishing a diagnosis
in young individuals is often difﬁcult. Since the age
of onset and the severity of the CHD in patients
with FH vary, it is difﬁcult to decide how aggressive
the treatment to prevent the progress of athero-
sclerosis should be and how to monitor the CHD
progression in these patients. The current FH
guidelines recommend that existing risk algorithms
such as Framingham risk score should not be used
in patients with FH.2 7 These risk scores are based
on data from general population and they signiﬁ-
cantly underestimate the lifetime CHD risk in
patients with FH who have grossly elevated LDL-C
levels since birth.
Polygenic versus monogenic FH
There are several lines of evidence to suggest that
the extent of atherosclerosis is likely to be higher in
monogenic compared with polygenic patients. The
Simon Broome Registry showed that patients with a
clinical diagnosis of deﬁnite FH had a higher stan-
dardised mortality ratio for CHD than those with a
clinical diagnosis of possible FH (2.94 vs 2.05).8
Since a mutation can be found in ∼80% of patients
with deﬁnite FH, the majority of this group have a
monogenic cause. By contrast, a mutation can only
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be detected in 25%–30% of patients with possible FH,9
meaning the majority of these ‘lower risk’ patients with FH
have a polygenic cause for their elevated LDL-C level.
A second body of evidence comes from the Simon Broome
DNA study where the prevalence of CHD in patients with the
three different genetic causes of FH was examined. After adjust-
ment for age, sex, smoking and blood pressure, compared with
the patients where no mutation had been identiﬁed, the OR for
having CHD in patients with the LDLR, APOB or PCSK9 muta-
tions were 1.84, 3.4 and 19.9, respectively (table 1), with an
overall signiﬁcant difference among groups (p=0.003).10 The
no-mutation group from the Simon Broome study was included
in the gene score analysis in the Talmud et al4 paper and had
the expected high gene score, that is, they had polygenic hyper-
cholesterolaemia. The implication of these data is that, com-
pared with those with a monogenic cause of FH, the prevalence
of CHD in those with a polygenic cause is lower.
There are several possible reasons why CHD risk is higher in
monogenic versus polygenic patients but is most likely to be due
to the fact that the monogenic group have had severely elevated
LDL-C level since birth, and thus, have a greater cumulative
‘LDL-C burden’,7 while the polygenic group have developed
elevated LDL-C level only with increasing age. It may also be
that in the polygenic group, other CHD risk factors are less
prevalent, for example, higher levels of lipoprotein(a) or lower
levels of high-density lipoprotein cholesterol (HDL-C), both of
which were suggested as being important in determining the
risk of CHD.5 Studies are needed to examine, for example,
carotid atherosclerosis by ultrasound or coronary calciﬁcation
by CT scan in these two patient groups. However, if conﬁrmed
that the level of atherosclerosis in polygenic patients is lower
than in monogenic patients with FH, it would suggest that these
individuals could be appropriately managed in the communities
under general practitioners and could, thus, be discharged from
hospital tertiary lipid clinics. This will allow the appropriate use
of resources for patients with a known mutation who are at
highest risk of CHD.
GENETIC AND BIOCHEMICAL RISK FACTORS
Genetic mutations that severely impair the function of LDLR
(null allele LDLR mutations) are associated with more advanced
degree of CHD and an earlier onset. The speciﬁc
gain-of-function PCSK9 mutation (p.Asp374Tyr), a common
mutation in lipoprotein lipase gene (p.Asn291Ser),11 ACE DD
genotype12 and genetic polymorphisms, for example, presence
of E2 and E4 alleles in apolipoprotein E,13 are known to
increase the CHD risk in patients with FH, while some PCSK9
loss-of-function variants and APOB gene mutations are
associated with a lower risk. Several genome-wide association
studies have identiﬁed common variants associated with increase
in the risk of CHD in the general population; however, no
genetic risk variant for CHD in individuals with FH has been
identiﬁed so far and the genetics of CHD risk in FH seems
more complex.14
Traditional risk factors such as age, male gender, smoking,
hypertension, higher LDL-C level and lower HDL-C level, all
play a role in patients with FH but their predictive value is differ-
ent from the general population.5 Not all the individuals with
FH develop atherosclerosis and CHD to same extent and they
might even show severe accelerated atherosclerosis despite no
features of metabolic syndrome. Although cardiovascular risk in
patients with FH is mainly driven by the degree of elevation of
LDL-C level, the risk of CHD in FH is not solely due to elevated
LDL-C level and its severity and clinical expression is even vari-
able within a family, where all relatives carry the same LDLR
gene defect.15 A family history of an early coronary event in ﬁrst-
degree or second-degree relatives generally puts the patient at
higher risk.14 Low HDL-C level and high total:HDL-C ratio are
strongly associated with a risk of CHD in FH.16
Lipoprotein(a) is an established risk factor for cardiovascular
disease17 and, irrespective of LDL-C levels, its serum level has
been consistently reported to be signiﬁcantly higher in patients
with FH, especially in those with an early CHD event.18
Lipoprotein(a) measurement is recommended in all subjects at
intermediate and high risk of CHD, for example, patients with
FH.17 There is limited evidence available in using new cardiac
biomarkers such as high-sensitivity C reactive protein and
inﬂammatory cytokines in risk stratiﬁcation of asymptomatic
patients with FH, which have been examined only in case–
control studies with small number of participants. Whether
there is any beneﬁt in adding genetic and novel biochemical bio-
markers in CHD risk prediction criteria for patients with FH
needs further large-scale studies.
Imaging techniques
Non-invasive imaging modalities might be another way to iden-
tify asymptomatic individuals with higher cardiovascular risk.
Imaging techniques were recommended to screen asymptomatic
people at intermediate and high risk in the 2012 European
Society of Cardiology Guidelines for Cardiovascular
Prevention.19
Carotid intima-media thickness measurement
Over the past few years, a large number of studies have reported
on the association between increased carotid intima-media thick-
ness (cIMT) and the risk of cardiovascular disease in the general
population. The ‘IMPROVE’, a multicentre European study,
showed that all cIMT measures (common, bifurcation and
internal carotid arteries) have a value in relation to an increased
risk of cardiovascular disease.20
The value of cIMT in cardiovascular risk stratiﬁcation in the
general population is an ongoing debate. Addition of cIMT
measurement to traditional cardiovascular risk prediction
models in the normal population does not lead to a signiﬁcant
increase in the performance of those models or leads to only a
small improvement in the risk prediction.21 However, several
clinical trials showed that the cIMT changes remain sensitive to
the changes in the LDL-C levels and it has been consistently
shown that cIMT can be used in evaluation of the carotid ath-
erosclerosis progression.
Individuals with FH have higher carotid IMT and femoral
IMT compared with people with normal lipid levels or other
Table 1 The OR for coronary heart disease (CHD) by mutation
type adjusted for risk factors (table from Humphries et al10)
Mutation
Patients
with
CHD (n)
Patients
without
CHD (n) OR (95% CI)*
None 55 101 1
LDLR 91 145 1.84 (1.10 to 3.06), p=0.02
APOB 6 4 3.40 (0.71 to 16.36), p=0.13
PCSK9 6 1 19.96 (1.88 to 211.55), p=0.01
*OR for having CHD adjusted for age, sex, smoking and systolic blood pressure at
recruitment compared with the patients where no mutation was identified.
APOB, apolipoprotein B; CHD, coronary heart disease; LDLR, LDL-receptor gene;
PCSK9, protein convertase subtilisin/kexin 9.
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types of inherited hypercholesterolaemia such as familial com-
bined hypercholesterolaemia.22 Also, among patients with FH,
individuals carrying LDLR null alleles have higher cIMT mea-
surements than those with LDLR defective alleles.23 The cIMT
in patients with FH might help to differentiate patients with a
severe form of FH with more advanced atherosclerosis who are
at higher risk of CHD.
The cIMT has been found to be signiﬁcantly higher among
dyslipidaemic children compared with children with normal
lipid levels.24 A 10-year follow-up study in statin-treated chil-
dren with FH and their unaffected siblings showed that the
mean cIMT was signiﬁcantly greater in children with FH even
after 10 years of treatment with lipid-lowering medication.
However, progression of the cIMT from baseline remained
similar in both groups.25
In addition to simple cIMT measurements, several new func-
tional parameters derived from cIMTultrasound images that are
currently under investigation might give valuable information to
identify patients with an elevated risk of future cardiovascular
events. These new parameters include three-dimensional cIMT
scanning to visualise vessel wall intima morphology26 and cIMT
variability to assess surface pattern and extent of abnormality in
carotid arteries.27
CT scan and MRI
Cardiac CT is a useful non-invasive imaging modality to assess
coronary artery atherosclerosis in symptomatic and asymptom-
atic high-risk patients. Coronary artery calciﬁcation has been
shown to be a surrogate marker for atherosclerosis, with the
calcium score ‘Agatston score’, being proportional to athero-
sclerosis plaque burden and cardiovascular risk.28 It has limita-
tion in its diagnostic value in accurately evaluating the severity
of CHD and plaque vulnerability. Direct examination of the
vessel lumen using CT coronary angiography has shown a diag-
nostic capability comparable with that of invasive methods for
visualisation of the anatomical details and degree of coronary
lumen stenosis and for assessment of the plaque burden.29
Dyslipidaemia is associated with an increased prevalence of
soft plaques. The key feature of this vulnerable subgroup of
plaques is the large lipid/necrotic core covered by a thin ﬁbrous
cap. Very few studies have been done on assessing plaque com-
position in patients with FH. Most data come from studies of
patients who underwent lipid-lowering therapies such as apher-
esis and reported a decrease in the lipid component of athero-
sclerotic plaques with aggressive treatment.
High-resolution cardiovascular magnetic resonance (CMR)
has become a reliable technique to assess atherosclerotic plaque
morphology, showing a good correlation with histopathology. It
is non-invasive and can reliably quantify carotid atherosclerosis.
Underhill et al30 carried out a double-blind trial in 43 patients
with raised cholesterol levels who received rosuvastatin for
24 months. They reported a signiﬁcant reduction in lipid-rich
necrotic core plaque in carotid arteries measured by 1.5-T
CMR, whereas the overall plaque burden remained unchanged
over the course of treatment. Whether the data on carotid
plaque burden will add more information to the current cardio-
vascular risk assessment in patients with FH is not clear.
Only a few studies have been done in asymptomatic patients
with FH to report calcium score and plaque burden by CT scan
or to assess aortic wall calciﬁcation and lipid-rich plaques by
MRI (table 2).31–41
Other techniques
A number of clinical studies conﬁrmed the association between
endothelial dysfunction and increased arterial stiffness with
higher risk of cardiovascular disease in general population.
Endothelial dysfunction in FH occurs from early age in child-
hood. In a study of 60 asymptomatic patients, 21 with a con-
ﬁrmed FH-causing mutation, 19 with an elevated LDL-C level
but no FH-causing mutation and 20 healthy controls, brachial
artery ﬂow-mediated dilation was signiﬁcantly lower in all
Table 2 Results of the studies with CT scan and MRI in asymptomatic individuals with heterozygous FH
Study FH subjects (n) Controls (n)
Imaging
technique Results
ten Kate et al31 67 30 healthy subjects CTCA Patients with FH had greater coronary calcium score.
Viladés Medel et al32 50 70 healthy subjects CTCA Patients with FH had a greater prevalence, extension and
severity of subclinical CHD.
Ten Kate et al33 59 patients with FH with
null mutation
86 patients with FH with reduced
or normal LDLR function
CTCA LDLR-negative patients had higher number of diseased
coronary artery segments per patient.
Neefjes et al34 140 patients with FH
with follow-up scans
– CTCA About 54% of all coronary plaques were calcified.
Neefjes et al35 101 126 patients without FH having
non-angina chest pain
CTCA Total calcium score was significantly higher in patients with
FH.
Miname et al36 102 35 healthy subjects CTCA Patients with FH had a significantly higher number of
plaques, stenosis, segments with plaques and calcium scores.
Martinez et al37 89 31 healthy subjects 16 or 64 sliced
CT
Coronary artery calcification prevalence and severity were
higher in FH.
Ye et al38 32 34 healthy subjects Electron-beam
CT
Coronary artery calcification was higher in FH.
Caballero et al39 36 19 healthy subjects MRI of aorta Atherosclerotic plaques in descending aorta were significantly
higher in FH cases.
Soljanlahti et al40 39 25 healthy subjects MRI of aorta No difference in any of the morphological or functional aortic
parameters between patients and controls detected.
Schmitz et al41 11 26 subjects MRI of aorta The descending thoracic aorta wall area was significantly
larger in patients with FH.
CHD, coronary heart disease; CTCA, CT coronary angiography; FH, familial hypercholesterolaemia; LDLR, LDL-receptor gene.
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patients with a raised LDL-C level compared with the healthy
group, but arterial stiffness parameters were similar.42 This sug-
gests that the FH mutation by itself is not a main indicator of
endothelial dysfunction and that other factors are involved.
Invasive methods are not recommended for risk stratiﬁcation
in asymptomatic patients. Myocardial perfusion imaging modal-
ities, such as stress echocardiography, nuclear myocardial perfu-
sion tests and magnetic resonance myocardial perfusion
imaging, are only recommended for patients presenting with the
clinical symptom of chest pain. Methods such as intravascular
ultrasound and optical coherence tomography as well as the
near-infrared spectroscopy (NIRS) have been used to assess
plaque morphology in coronary arteries recently; however, there
are not enough data available in their usage in asymptomatic
patients.
CHD RISK IN HOMOZYGOUS FH
Homozygous FH (HoFH) is a rare condition with a prevalence
of one to three cases per million in most populations.43 It is
characterised by extremely accelerated atherosclerosis that
occurs in coronary arteries and in all major arteries in the body,
for example, carotid arteries, thoracic aorta, renal arteries and
other peripheral arteries. The ﬁrst major cardiovascular event in
these patients often occurs during adolescence with angina and
myocardial infarction in early childhood, typically in the indivi-
duals who are LDLR-negative.44 The newer imaging techniques
might be useful in HoFH cases. HoFH is typically refractory to
existing lipid-lowering medications and therefore lipoprotein
apheresis is recommended in patients with HoFH as soon as
possible, ideally by age 5 and not later than 8 years.45
TREATMENT AND PREVENTION
The UK NICE guideline recommends statins as the ﬁrst-line
treatment for patients with FH and a reduction of at least 50%
in LDL-C concentration from baseline level.2 A decrease in
serum LDL-C levels should have an inﬂuence on prevalence of
soft plaques and plaque composition and may lower the fraction
of vulnerable plaques among atherosclerotic lesions.
In FH, primary prevention interventions are more effective in
terms of absolute number of prevented deaths than interven-
tions in the setting of secondary prevention. The major beneﬁt
of statin treatment appears to be in primary prevention of fatal
coronary disease. Data from Simon Broome Registry in the UK
(1980–2006) showed 48% reduction in CHD mortality, from a
twofold excess to none, when statin was taken for primary
prevention compared with 25% reduction when only stains
were used for secondary prevention (ﬁgure 1).46 Based on data
from Starr et al47 study, LDL burden would be delayed in early
treated subjects with FH by 5 years in comparison to the sub-
jects starting statin treatment at the age of 18 (ﬁgure 2).48 This
suggests that with earlier diagnosis and treatment, it should be
possible to prevent any excess coronary mortality in early
adulthood.
For a small proportion of patients with FH with very high
LDL-C level, who have progressive coronary disease despite
maximal statin treatment or who are statin intolerant, the
PCSK9 inhibitors may offer additional therapeutic options in
future. These have been shown to effectively reduce LDL-C
levels in patients with heterozygous FH and patients with
HoFH who have some residual LDLR activity that can be
rescued by PCSK9 blockade,49 but not in those with LDLR null
alleles.50 Since patients with the PCSK9 mutation have the
highest untreated and on-treatment LDL-C levels and the
highest CHD risk,10 this group may be appropriate for these
agents. By contrast, those with a clinical diagnosis of FH but
with no detectable mutation but a polygenic high LDL-C single-
nucleotide polymorphism score as their genetic cause are likely
to be adequately treated with more modest doses of currently
available statin agents. Thus, a better understanding of the
genetic aetiology of the FH phenotype in the future should
enable the prioritisation of patients with the most severe form
of FH, who are at higher risk of cardiovascular events, to use
these new treatments.
CONCLUSION
Currently, there is limited evidence available to guide the
optimum cardiovascular risk stratiﬁcation of patients with FH.
Traditional risk factors are insufﬁcient for risk prediction in this
young group of patients and other methods such as non-invasive
imaging might produce information that is more reliable.
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Figure 1 Standard mortality ratio (SMR)-fold excess for coronary
heart disease (CHD) in patients with a diagnosis of familial
hypercholesterolaemia (FH) with and without statin treatment (1980–
1991 vs 1992–2006) is shown. (Data from Neil et al,46 2766 deﬁnite
and possible patients with FH (1456 men and1310 women) with 190
CHD deaths observed and 37 727 person-years follow-up.)
Figure 2 Cumulative LDL burden, expressed as mmol/L/year, over a
lifetime in individuals having non-familial hypercholesterolaemia (FH)
and individuals having FH with and without treatment showing
threshold for coronary heart disease. (Data from Starr et al47 and
Vuorio et al48.) LDL-C, low-density lipoprotein cholesterol.
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